摘要
目的评价血清人附睾分泌蛋白4含量检测在卵巢癌诊断中的价值。方法系统地检索维普、清华同方、NCBIPubMed、EMBASE数据库中2000-2010年符合纳入标准的国内外公开发表的有关血清人附睾分泌蛋白4在卵巢癌诊断中价值的文献16篇,通过随机效应模型综合分析合并效应量,采用RevMan4.2.10统计软件分析。结果人附睾分泌蛋白4诊断卵巢癌的敏感性为73%,95%可信区间为0.68～0.82;特异性为0.95,95%可信区间为0.93～0.98;阳性预测值为0.89,95%可信区间为0.83～0.95;阴性预测值为0.85,95%可信区间为0.80～0.90。结论人附睾分泌蛋白4作为卵巢肿瘤标志物在卵巢癌的诊断中有一定价值。
Objective To evaluate the value of serum HE4 content testing on diagnosis for ovarian cancer. Methods We searched for 16 articles through all literature from 2000 to 2010 about testing of serum HE4 content in patients with ovarian cancer to be searched systematically from VIP, Qing Hua Tong Fang, MEDLINE, NCBI PubMed and EMBASE database. Results were combined with random effects models. RevMan 4.2.10 software was applied to process data. Results The sensitivity of serum HE4 in human ovarian carcinoma was 73%, 95% confidence interval, 0.68 to 0.82; the specificity was 0.95, 95% confidence interval, 0.93 to 0.98; the positive predictive was 0.89, 95% confidence interval, 0.83 to 0.95; the negative predictive was 0.85, 95% confidence interval, 0.80 to 0.90. Conclusion This meta-analysis confirms that HE4 as ovarian tumor biomarkers has some value on diagnosis ovarian cancer.
出处
《循证医学》
CSCD
2012年第3期163-168,共6页
The Journal of Evidence-Based Medicine
